Libby's H*O*P*E*

*Helping*Ovarian Cancer Survivors*Persevere Through*Education

Menu

Skip to content
  • Home
  • About
  • Mission
  • Warning Signs & Symptoms
  • Ovarian Cancer Overview
  • Prevention, Early Detection/Screening & Causes
  • Genetics
  • Types of Ovarian Cancer
  • Diagnosis & Staging
  • Treatment Overview
  • Surgery
  • Chemotherapy
  • Radiology & Radiation Therapy
  • Hormonal (Anti-Estrogen) Therapy
  • Biological (Immunotherapy & Vaccine) Therapy
  • Gene Therapy
  • Alternative & Complementary Therapy
  • Clinical Development
  • Clinical Trials
  • Coping
  • Survivorship
  • Ovarian Cancer Resources
  • Contact

Tag Archives: James P. Wilmot Cancer Ctr.

Ginger Quells Cancer Patients’ Chemotherapy-Related Nausea

Posted on May 16, 2009 by Paul Cacciatore

“People with cancer can reduce post-chemotherapy nausea by 40 percent by using ginger supplements, along with standard anti-vomiting drugs, before undergoing treatment, according to scientists at the University of Rochester Medical Center. …”

Continue reading →

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on Pinterest (Opens in new window) Pinterest
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Reddit (Opens in new window) Reddit
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email
Like Loading...
Posted in Alternative Medicine, Chemotherapy, Coping, Meeting Highlights | Tagged 2009 ASCO Annual Mtg., Anzemet, Community Clinical Oncology Program Research Base, Complementary & Alternative Medicine, ginger, James P. Wilmot Cancer Ctr., Julie L. Ryan Ph.D. M.P.H., National Cancer Institute, Novaban, ovarian cancer, Univ. of Rochester Medical Ctr., Zofran | Leave a comment
"Once you choose hope, anything is possible." -- Christopher Reeve

Categories

RSS Google Ovarian Cancer News

  • Lipids in ovarian cancer ascites impair T cell activation by disrupting TCR dynamics - Nature
  • Spontaneous Tumor Lysis Syndrome Revealing Advanced Ovarian Carcinoma: From Oncologic Emergency to Complete Pathologic Response - Cureus
  • J&J beats lawsuit alleging that talc caused three women's cancer - Reuters
  • Breakthrough ovarian cancer drug offers patients more time and better quality of life - BBC
  • New ovarian cancer treatment approved for NHS - the first for 20 years - Sky News
  • Chris Evert Reveals She Has Been Diagnosed with Ovarian Cancer for the Third Time, Says the Disease Is ‘Relentless’ - People.com
  • Life-prolonging drug for advanced ovarian cancer gets go-ahead in England - The Guardian
  • New immune mechanism helps explain why ovarian cancer stops responding to chemotherapy - Medical Xpress
  • IMNN-001 Plus Chemo Cuts MRD Rate in Frontline Ovarian Cancer - Targeted Oncology
  • IMUNON’s IMNN-001 Shows Lower Residual Disease in Phase 2 Ovarian Cancer Study - The Clinical Trial Vanguard

Top Posts

  • CNTO 328 Shows Promise For Ovarian Cancer In Small Clinical Trial, Say U.K. Scientists.
    CNTO 328 Shows Promise For Ovarian Cancer In Small Clinical Trial, Say U.K. Scientists.
  • About
    About
  • Can Talcum Powder Cause Ovarian Cancer?
    Can Talcum Powder Cause Ovarian Cancer?
  • 2009-2010 U.S. News & World Report Best U.S. Hospital Rankings
    2009-2010 U.S. News & World Report Best U.S. Hospital Rankings
  • PI3K Pathway:  A Potential Ovarian Cancer Therapeutic Target?
    PI3K Pathway: A Potential Ovarian Cancer Therapeutic Target?
  • 2011 ASCO: Exelixis Reports Expanded Cabozantinib (XL184) Phase II Data For Advanced Ovarian Cancer; Six Deaths Reported
    2011 ASCO: Exelixis Reports Expanded Cabozantinib (XL184) Phase II Data For Advanced Ovarian Cancer; Six Deaths Reported
  • Preclinical Testing Suggests That Apoptosis Protein Inhibitor AT-406 Is Effective Against Ovarian Cancer; Initial Phase I Solid Tumor Clinical Trial Ongoing
    Preclinical Testing Suggests That Apoptosis Protein Inhibitor AT-406 Is Effective Against Ovarian Cancer; Initial Phase I Solid Tumor Clinical Trial Ongoing
  • Contact
    Contact
  • PARP Inhibitor Olaparib Benefits Women With Inherited Ovarian Cancer Based Upon Platinum Drug Sensitivity
    PARP Inhibitor Olaparib Benefits Women With Inherited Ovarian Cancer Based Upon Platinum Drug Sensitivity
  • Working Smarter, Not Harder: Use of Anti-Estrogen Therapy to Battle Recurrent Ovarian Cancer
    Working Smarter, Not Harder: Use of Anti-Estrogen Therapy to Battle Recurrent Ovarian Cancer

Archives

  • May 2015
  • September 2014
  • August 2014
  • May 2014
  • March 2014
  • August 2013
  • May 2013
  • February 2013
  • January 2013
  • July 2012
  • June 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008

Blog Stats

  • 511,202 Visitors
cancer blog

Enter your email address to subscribe to Libby's H*O*P*E* & receive notifications of new posts by email.

Join 342 other subscribers

 Subscribe in a reader

Click on the orange button above if you want to (i) add Libby's H*O*P*E*(tm) updates to a web-based or other reader, or (ii) embed a Libby's H*O*P*E* (tm) update widget on your desktop, website or blog.

Donate To Ovarian Cancer Research

OCRF is the largest U.S. private funding agency supporting ovarian cancer research. It is a not-for-profit, 501(c)(3) organization. Click on the OCRF logo above to make a donation.

Strategic Partners

Podcasts

Join Us In the Fight Against Ovarian Cancer

RSS New Ovarian Cancer Clinical Trials (Past 14 Days)

  • A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery
  • Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab
  • Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
  • A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer
  • A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors
  • A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
  • DBC-664 in Adult Patients With Solid Tumors
  • [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
  • A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors

RSS New Adult Solid Tumor Clinical Trials (Past 14 Days)

  • A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002
  • 18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
  • Phase II Study of QLC2519 in Pediatric Solid Tumor Participants
  • A Nutrition and Exercise Program With Olanzapine Compared to Olanzapine Alone: A Trial in Patients With Advanced Tumors
  • Symptom Management to Improve Completion of Patient-reported Outcome Measures
  • ML-016 in Advanced Cancer With Lung and/or Liver Involvement
  • Bevacizumab Plus Nab-paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsule (S-1) as Second-line Treatment for Advanced Biliary Tract Cancer: a Phase Ⅱ Clinical Trial
  • A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
  • A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
  • HMPL-A830 in Solid Tumors

RSS Medical Studies

  • Clinicopathological Spectrum of Ovarian Tumors and Diagnostic Utility of Cancer Antigen 125 (CA-125): An Observational Study From Eastern India
  • Single-cell and spatial profiling reveal an IL-10-associated iCAF-M2 macrophage communication axis in high-grade serous ovarian cancer ascites
  • NLRP12 in cancer: a context-dependent regulator of tumor progression, immunity, and metabolism
  • Durable response to pembrolizumab plus axitinib in platinum-resistant ovarian clear cell carcinoma: A case report
  • In silico evaluation of the role of PEA3 subfamily ETS transcription factors in chemoresistance in ovarian cancer
  • Trends and disparities in ovarian cancer incidence and mortality in the United States, 1999 to 2023: A population-based ecological trend analysis
  • Association between pelvic inflammatory disease and ovarian cancer: A bidirectional Mendelian randomization study
  • Recent Advances in Genetic Testing and Clinical Management of Hereditary Breast and Ovarian Cancer (HBOC) in India
  • Pre-operative Nutritional Risk Screening 2002-based nomograms for predicting post-operative complications after cytoreductive surgery for ovarian cancer: a multi-center retrospective cohort study
  • Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting

Recent Comments

Prometey Bank's avatarPrometey Bank on World Ovarian Cancer Day: Toge…
mikaljhohnashly's avatarmikaljhohnashly on World Ovarian Cancer Day: Toge…
Jan C. Calthrop's avatarJan C. Calthrop on Lab-On-A-Chip: Veridex & M…
Paul Cacciatore's avatarPaul Cacciatore on About
Building a Team for… on About
Kathleen's avatarKathleen on About
Paul Cacciatore's avatarPaul Cacciatore on About
Liz's avatarLiz on About
Paul Cacciatore's avatarPaul Cacciatore on Dana Farber Webchat: The Lates…
Judith Marengere's avatarJudith Marengere on Dana Farber Webchat: The Lates…
Paul Cacciatore's avatarPaul Cacciatore on Dana Farber Webchat: The Lates…
Franca Pichini's avatarFranca Pichini on Dana Farber Webchat: The Lates…
painspeaks's avatarpainspeaks on SU2C Announces the Formation o…
marcy westerling's avatarmarcy westerling on SU2C Announces the Formation o…
anne's avataranne on Dana-Farber Oncologists Differ…

Blogroll

  • Site Meter Site Meter

Cancer Organizations

  • American Cancer Society
  • National Cancer Institute

Everyday Heroes

  • Are You There Cancer? It's Me, Jennie.
  • Bald Heads Are Sexy
  • Butterfly Ballet
  • Cancer Queen
  • Carrie's Journey
  • Chris Bledy
  • Diary of a Cancer Patient
  • I Want To Breathe
  • Janine's News
  • Journey Through Ovarian Cancer
  • Kristi & Brian: Living! With Cancer
  • Laurey Bikes
  • Life Cycle
  • livingly dying
  • Marcheline Bertrand Remembered
  • Meghan's Message
  • Monday Hearts For Madalene
  • My Journey With Teal
  • Nobody Has Ovarian Cancer
  • Out Shine Ovarian Cancer
  • OVACOM
  • Ovarian Cancer News
  • Ovarian Cancer?? pass the wine … now!
  • Scrambled Eggs, Surviving Ovarian Cancer
  • Shannon Miller Lifestyle
  • Still Smiling
  • Strong As Steele
  • Tenaciously Teal
  • The Carcinista
  • What? Me Worry?
  • Will There Be Cows In Heaven?
  • Women of Teal

Inspirational Cancer Advocates

  • Bald Is Beautiful
  • Bicycling For Ovarian Cancer (Craig Broeder)
  • Christine Druther
  • Fran Drescher
  • Imerman Angels
  • Jenn Sommermann: Training For a Cure
  • Jim Valvano
  • Laurey Masterton
  • Maddie Kullen
  • Mothers With Cancer
  • Randy Pausch
  • Sean Swarner
  • Standup2cancer
  • The Rock Band N.E.D.

Ovarian Cancer News Archive

  • Ovarian Cancer News Archive

Ovarian Cancer Organizations

  • National Breast & Ovarian Cancer Connection
  • National Ovarian Cancer Coalition
  • Ovarian Cancer National Alliance
  • Ovarian Cancer Research Fund
  • Ovations For the Cure

U.S. Treatment Centers

  • National Comprehensive Cancer Network Member Institutions
  • NCI-Designated Cancer Centers

Video Archive

  • Ovarian Cancer Video Library
Copyright 2008 - 2016 Paul Cacciatore, Libby's H*O*P*E*(TM), *Helping *Ovarian Cancer Survivors *Persevere Through *Education(TM), all rights reserved.
Paul Cacciatore

Create Your Badge
Site Meter
Blog at WordPress.com.
  • Subscribe Subscribed
    • Libby's H*O*P*E*
    • Join 217 other subscribers
    • Already have a WordPress.com account? Log in now.
    • Libby's H*O*P*E*
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar
%d